Publications in collaboration with researchers from University Hospital of Zurich (60)

2024

  1. Heart failure in Europe: Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction – the ESC EORP Heart Failure III Registry

    European Journal of Heart Failure

  2. Left ventricular ejection fraction digit bias and reclassification of heart failure with mildly reduced vs reduced ejection fraction based on the 2021 definition and classification of heart failure

    American Heart Journal, Vol. 267, pp. 52-61

2023

  1. 2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 1, pp. 48-56

  2. Acute heart failure and valvular heart disease: A scientific statement of the Heart Failure Association, the Association for Acute CardioVascular Care and the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology

    European Journal of Heart Failure, Vol. 25, Núm. 7, pp. 1025-1048

  3. Association of vocational interventions and work-related factors with disease and work outcomes in people with RMDs: A systematic review

    Seminars in Arthritis and Rheumatism, Vol. 58

  4. Comprehensive characterization of non-cardiac comorbidities in acute heart failure: an analysis of ESC-HFA EURObservational Research Programme Heart Failure Long-Term Registry

    European journal of preventive cardiology, Vol. 30, Núm. 13, pp. 1346-1358

  5. How does age affect outcomes after left ventricular assist device implantation: results from the PCHF-VAD registry

    ESC Heart Failure, Vol. 10, Núm. 2, pp. 884-894

  6. Hyponatraemia and changes in natraemia during hospitalization for acute heart failure and associations with in-hospital and long-term outcomes – from the ESC-HFA EORP Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 25, Núm. 9, pp. 1571-1583

  7. Machine learning to predict major bleeding during anticoagulation for venous thromboembolism: possibilities and limitations

    British Journal of Haematology, Vol. 201, Núm. 5, pp. 971-981

  8. Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry

    European Heart Journal, Vol. 44, Núm. 17, pp. 1526-1529

  9. Prevalence, characteristics and prognostic impact of aortic valve disease in patients with heart failure and reduced, mildly reduced, and preserved ejection fraction: An analysis of the ESC Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 25, Núm. 7, pp. 1049-1060

  10. Prevalence, clinical characteristics and outcomes of heart failure patients with or without isolated or combined mitral and tricuspid regurgitation: An analysis from the ESC-HFA Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 25, Núm. 7, pp. 1061-1071

  11. Rationale and design of the ESC Heart Failure III Registry – Implementation and discovery

    European Journal of Heart Failure, Vol. 25, Núm. 12, pp. 2316-2330

  12. Sex-related differences in left ventricular assist device utilization and outcomes: results from the PCHF-VAD registry

    ESC Heart Failure, Vol. 10, Núm. 2, pp. 1054-1065

  13. Surgeons’ perspectives on artificial intelligence to support clinical decision-making in trauma and emergency contexts: results from an international survey

    World Journal of Emergency Surgery, Vol. 18

2022

  1. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction – insights from the ESC-HFA EORP Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 24, Núm. 2, pp. 335-350

  2. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

    Annals of Oncology, Vol. 33, Núm. 2, pp. 181-192

  3. Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): Systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs

    RMD Open, Vol. 8, Núm. 2

  4. Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs

    RMD open, Vol. 8, Núm. 1

  5. Impact of progressive aortic regurgitation on outcomes after left ventricular assist device implantation

    Heart and Vessels, Vol. 37, Núm. 12, pp. 1985-1994